BRIEF-Novus Therapeutics Announces First Patient Enrolled In Phase 2A Clinical Trial Of Anti-Cd40l Antibody At-1501 In Amyotrophic Lateral Sclerosis

Reuters
Nov 02, 2020

Nov 2 (Reuters) - Novus Therapeutics Inc :

* NOVUS THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2A CLINICAL TRIAL OF ANTI-CD40L ANTIBODY AT-1501 IN AMYOTROPHIC LATERAL SCLEROSIS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10